MedTrace Logo

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects

NCT06014853 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-02-05

No results posted yet for this study

Summary

Study Design : A randomized, open-label, four-sequence, four-period, crossover, single dosing, phase 1 study

Conditions

Interventions

DRUG

SOL-804-F

All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.

DRUG

Zytiga

All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.

Sponsors & Collaborators

  • Dyna Therapeutics

    collaborator UNKNOWN

  • Bukwang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • SeungHwan Lee · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-10
Primary Completion
2023-10-28
Completion
2023-11-16

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06014853 on ClinicalTrials.gov